Robotic surgery advertising: FDA safety communications, cleared uses and claims you can support

Robotic-assisted surgery is advertised heavily: billboards, procedure pages, search ads, hospital magazines and surgeon profiles all feature the console and the arms. The device itself is a selling point, and that is exactly where the risk sits. Copy written around the machine can slide into claims that belong to a clinical study, not to a brochure: less pain, faster recovery, better results, safer surgery, cancer care. This guide is for surgeons, surgical groups, hospitals and ambulatory surgery centers that offer robotic-assisted procedures, and for the agencies that write their pages and ads.

Two related topics have their own guides and are not repeated here. What “approved”, “cleared”, “registered” and “listed” mean for any device, and why intended use limits what an ad can say, is in our guide to medical device marketing claims. Marketing for orthopedic practices, including joint replacement pages and sports medicine, is in our orthopedic practice marketing guide. For first, only and best claims in general, see our guide to superlative claims in healthcare ads. Hernia practices that advertise robotic repair should also read hernia surgery center marketing.

What FDA says the device is, and is not

Start with FDA’s own description, because it settles two wording questions before any campaign begins. The FDA page on computer-assisted surgical systems says robotically-assisted surgical (RAS) devices enable the surgeon to use computer and software technology to control and move surgical instruments through one or more tiny incisions. It also says: “The device is not actually a robot because it cannot perform surgery without direct human control.”

That sentence is a useful test for copy. Ads that say “the robot performs your surgery”, “precision of a machine” or “surgery without human error” give the impression that the device operates on its own or removes the surgeon’s judgment. FDA describes the opposite. Write “robotic-assisted surgery performed by [Surgeon name]” or “surgery using a robotic-assisted system”, and keep the surgeon as the subject of the sentence.

The same page lists the uses FDA has cleared: RAS devices for use by trained physicians in an operating room environment for laparoscopic surgical procedures in general surgery, cardiac, colorectal, gynecologic, head and neck, thoracic and urologic surgical procedures. Your procedure pages should sit inside the cleared indications for the specific system you use. If a procedure falls outside them, that is a clinical decision for the surgeon and the patient, and FDA’s statute says it does not limit a practitioner’s authority to use a legally marketed device within a legitimate practitioner-patient relationship (21 U.S.C. 396). Advertising that use as an FDA-backed service is a different matter, and it is where the cancer caution below applies.

The FDA safety communication on cancer and mastectomy

FDA issued a safety communication on February 28, 2019 titled “Caution When Using Robotically-Assisted Surgical Devices in Women’s Health including Mastectomy and Other Cancer-Related Surgeries”, and the computer-assisted surgical systems page now carries its update. As checked on October 30, 2026, that page says FDA has become aware of continued use of RAS devices for the prevention of cancer and treatment of patients with cancer, and that “the FDA has not granted marketing authorization for any RAS devices specifically for the prevention or treatment of cancer.”

The page explains what has been cleared and what has not. FDA has cleared RAS devices for certain procedures performed in patients with cancer, such as hysterectomy, prostatectomy and colectomy. Those clearances “are based on short-term (30 day) patient follow up.” The page then says the safety and effectiveness of RAS devices for the prevention and treatment of cancer, based on cancer-related outcomes such as overall survival, recurrence and disease-free survival, “have not been established.” On mastectomy, it says FDA has not granted any RAS device marketing authorization for that procedure and that there is little evidence on safety and effectiveness. On cervical cancer, it notes limited reports that found minimally invasive surgery, including laparoscopic and robotic-assisted surgery, associated with lower long-term survival than open abdominal surgery, and other reports that found no significant difference.

For marketing, that leads to four wording rules:

• Do not write “robotic cancer surgery” as if the device treats cancer. Describe the procedure instead: “robotic-assisted prostatectomy” or “robotic-assisted hysterectomy”, with the cancer care decisions credited to the care team.
• Do not claim or imply better cancer outcomes from the robotic approach, such as fewer recurrences, cleaner margins or longer survival, since FDA says those outcomes have not been established for the device.
• Do not advertise robotic-assisted mastectomy as an available service backed by FDA. FDA says no RAS device has marketing authorization for it.
• When a page discusses surgical options for a cancer, say that the right approach depends on the patient and the cancer, and invite the patient to discuss the risks and benefits of each option with the surgeon.

FDA’s own advice to patients on the same page fits the last rule: robotically-assisted surgery “may not be appropriate in all situations”, and patients should talk to their physician about the risks and benefits of robotic-assisted surgery and of other treatment options. Copy that echoes this advice is safer than copy that argues against it.

Cleared, not approved, and no FDA endorsement

RAS devices reach the market through FDA’s premarket notification process. FDA’s 510(k) page describes a 510(k) as a premarket submission made to demonstrate that the device is as safe and effective, that is, substantially equivalent, to a legally marketed device. FDA’s page on device approvals and clearances distinguishes that from premarket approval (PMA), which is based on a determination that there is sufficient valid scientific evidence to provide reasonable assurance of safety and effectiveness.

The difference matters for copy. Under 21 CFR 807.97, a finding of substantial equivalence “does not in any way denote official approval of the device”, and any representation that creates an impression of official approval because of the premarket notification is misleading. That rule is aimed at the device, but a practice ad that says “FDA-approved robotic surgery” creates the same impression for patients, and the FTC judges ads by the net impression they leave. Our device claims guide covers the vocabulary in full. For robotic surgery pages, three points are enough:

• Avoid “FDA approved” for the system or the surgery. If you mention FDA at all, use the exact status for the exact indication, checked against FDA’s database.
• FDA clearance is for the device and its indications. It is not a statement about your hospital, your surgeon or your results, so do not place it next to outcome claims as if it supported them.
• Do not name the device brand in ads unless counsel has cleared the trademark use. Patients choose a surgeon and a hospital, and the copy should be about the care you give.

Less pain, faster recovery and other comparative claims

The claims that do the heavy lifting in robotic surgery ads are comparisons: smaller incisions, less pain, less blood loss, shorter hospital stay, faster return to work, fewer complications. Each one compares the robotic-assisted approach with something else, such as open surgery or conventional laparoscopy. Under 15 U.S.C. 45 and 15 U.S.C. 52, deceptive acts and false advertisements for services and devices are unlawful, and the FTC’s Health Products Compliance Guidance explains how it applies those laws to health claims.

Three points from that guidance shape comparative claims. First, claims about health benefits or safety need substantiation in the form of competent and reliable scientific evidence, and the guidance says that, as a general matter, this will need to be randomized, controlled human clinical testing. Second, when an ad can reasonably be read more than one way, the advertiser has to substantiate each reading. Third, anecdotal evidence about individual experiences, including surveys of patients, is never sufficient to substantiate claims about the effects of a health product.

Put that against a familiar ad line. “Robotic surgery means less pain and a faster recovery” can be read as a comparison with open surgery, with laparoscopy, or with both, and as a promise to each patient. To support it, you would need evidence that matches the procedure, the comparison and the claim, and FDA’s own page notes that clearances for cancer-related procedures rest on 30-day follow up. Safer patterns:

• Describe the approach rather than the outcome: “surgery through several small incisions instead of one larger incision” is a description of the technique.
• If you make a comparative claim, name what you are comparing with, attribute the evidence, and keep the claim no broader than the evidence. “[Study or society statement, date] reported shorter hospital stays for [procedure] with [approach] compared with open surgery” is checkable; “heal faster” is not.
• Add that recovery depends on the patient, the procedure and other factors, and that the surgeon will discuss what to expect.
• Keep risk information in view. The HPCG says that ads making an express or implied safety representation should include information about significant safety risks, and the FDA page records reports of injuries and deaths related to RAS devices.

Do not quote recovery times, complication rates or pain scores from a manufacturer brochure as if they were your own, and do not quote them at all unless the source is named, dated and matches the procedure on the page.

Surgeon experience claims

Surgeon experience is the strongest honest message in this service line, and FDA points patients toward it. The computer-assisted surgical systems page says patients should “feel free to inquire about their surgeon’s training and experience with these devices.” It also says FDA does not supervise or provide accreditation for physician training, that training is the responsibility of the manufacturer, physicians and health care facilities, and that physicians, hospitals and facilities that use RAS devices should ensure surgeons are trained properly and have appropriate credentials.

Experience claims are factual claims, so they need records behind them:

• Procedure counts: “[Surgeon name] has performed more than [number] robotic-assisted [procedure] procedures” only if your case logs show it, counted the way the sentence reads (as primary surgeon, at your facility or elsewhere, through a stated date). Update the number and the date together.
• Training: name the training accurately. Do not present a manufacturer course, a hospital privilege or a proctoring arrangement as board certification or as an FDA credential. FDA says it does not accredit physician training.
• Superlatives: “leading robotic surgeon in [region]”, “first in the state” or “center of excellence” are comparative claims. Use them only with a named, dated source that supports the exact wording, and remove them when the source no longer does.
• Program size: a number of systems or cases at a hospital is not evidence of better outcomes for each patient. Do not pair it with outcome language.

Experience claims belong to the surgeon who has the experience. A group page should not borrow one surgeon’s case count for every surgeon listed on it.

Patient stories and videos

Recovery stories are persuasive, which is why the FTC rules on endorsements apply to them. Under 16 CFR 255.2(a), the advertiser must substantiate claims made through consumer endorsements in the same manner as if it had made them directly, and consumer endorsements themselves are not competent and reliable scientific evidence. Under 255.2(b), an endorsement about a key attribute will likely be read as representing what consumers will generally achieve, so without substantiation for that, the ad should clearly and conspicuously disclose the generally expected performance. A patient saying “I was back at work in a week” makes a recovery claim, and the same substantiation rules apply.

Patient stories also involve health information. Using a patient’s protected health information for marketing needs a written authorization under 45 CFR 164.508(a)(3). Get the authorization before filming, keep it with the asset, and stop using the story if the patient revokes it.

Illustration: two ways to advertise robotic surgery

Illustration: [Hospital name] runs a search ad and landing page that read “Robotic cancer surgery. FDA-approved technology. Less pain, faster recovery, better results.” The page features a patient video about a quick return to the gym and lists the number of robotic systems the hospital owns. Each sentence raises a problem covered above: the device is not authorized to treat cancer, clearance is not approval, the comparative claims have no named evidence behind them, and the video implies a recovery other patients can expect.

Illustration: [Practice name] runs a page for robotic-assisted hysterectomy that reads “Robotic-assisted hysterectomy, performed by [Surgeon name], through several small incisions. Whether this approach is right for you depends on your diagnosis and health, and [Surgeon name] will go over the risks and benefits of each option with you.” The surgeon profile states their case count as of a date and the training they completed, worded as it appears on their records. A patient video carries a written authorization and a clear statement that recovery differs from patient to patient. The page links to the practice’s general information on preparing for surgery.

Checklist before a robotic surgery campaign goes live

• The surgeon, not the device, is the subject of the copy, and nothing says or implies that the device operates on its own.
• Every procedure advertised is inside the cleared indications for the system you use.
• No claim that the device treats or prevents cancer or improves cancer outcomes, and no robotic-assisted mastectomy offered as an FDA-backed service.
• No “FDA approved”; any FDA status statement is exact and checked.
• Each comparative claim names its comparison and its source and is no broader than the source.
• Significant risks are mentioned where safety or recovery is promoted.
• Surgeon case counts, training and superlatives match records and carry a date.
• Patient stories have written authorization and a generally expected results disclosure where needed.

How we help

We build websites, local search, Google Ads and AI front desk tools for independent practices and health businesses. For a surgical practice or hospital program, that means procedure and surgeon pages that describe the approach accurately and keep experience figures dated and easy to update, ad copy that stays inside what the evidence supports, and consultation request forms that keep health information away from tracking tools. We do not decide what a device is cleared for, what evidence supports a claim or which procedure suits a patient; your surgeons and counsel do. Our tools are built with HIPAA in mind. We confirm in writing what a BAA covers before any patient information flows through a tool, and if it is not covered, we do not route patient information through it. We are not a healthcare provider and we do not give legal or medical advice. We do not sell lead lists and we do not pay for referrals. For the wider rules, see our healthcare marketing rules hub.

Sources

• FDA: Computer-Assisted Surgical Systems (including the update to the February 28, 2019 safety communication)
• FDA: Premarket Notification 510(k)
• FDA: Device Approvals and Clearances
• 21 CFR 807.97: Misbranding by reference to premarket notification
• 21 U.S.C. 396: Practice of medicine
• 15 U.S.C. 45: Unfair methods of competition and unfair or deceptive acts or practices
• 15 U.S.C. 52: Dissemination of false advertisements
• FTC: Health Products Compliance Guidance (December 2022)
• 16 CFR 255.2: Consumer endorsements
• 45 CFR 164.508: Uses and disclosures for which an authorization is required

More in Physician specialty marketing